NO304829B1 - 3-substituerte oksindolderivater som kaliumkanalmodulatorer - Google Patents

3-substituerte oksindolderivater som kaliumkanalmodulatorer

Info

Publication number
NO304829B1
NO304829B1 NO962232A NO962232A NO304829B1 NO 304829 B1 NO304829 B1 NO 304829B1 NO 962232 A NO962232 A NO 962232A NO 962232 A NO962232 A NO 962232A NO 304829 B1 NO304829 B1 NO 304829B1
Authority
NO
Norway
Prior art keywords
potassium channel
channel modulators
oxindole derivatives
substituted oxindole
substituted
Prior art date
Application number
NO962232A
Other languages
English (en)
Norwegian (no)
Other versions
NO962232L (no
NO962232D0 (no
Inventor
Piyasena Hewawasam
Valentin K Gribkoff
Nicholas A Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO962232D0 publication Critical patent/NO962232D0/no
Publication of NO962232L publication Critical patent/NO962232L/no
Publication of NO304829B1 publication Critical patent/NO304829B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
NO962232A 1995-06-07 1996-05-31 3-substituerte oksindolderivater som kaliumkanalmodulatorer NO304829B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/477,047 US5565483A (en) 1995-06-07 1995-06-07 3-substituted oxindole derivatives as potassium channel modulators

Publications (3)

Publication Number Publication Date
NO962232D0 NO962232D0 (no) 1996-05-31
NO962232L NO962232L (no) 1996-12-09
NO304829B1 true NO304829B1 (no) 1999-02-22

Family

ID=23894292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962232A NO304829B1 (no) 1995-06-07 1996-05-31 3-substituerte oksindolderivater som kaliumkanalmodulatorer

Country Status (25)

Country Link
US (2) US5565483A (fr)
EP (1) EP0747354B1 (fr)
JP (1) JP4011135B2 (fr)
KR (1) KR100432157B1 (fr)
CN (1) CN1076348C (fr)
AR (1) AR004493A1 (fr)
AT (1) ATE195515T1 (fr)
AU (1) AU707760B2 (fr)
BR (1) BR1100180A (fr)
CA (1) CA2176183C (fr)
CZ (1) CZ289248B6 (fr)
DE (1) DE69609772T2 (fr)
DK (1) DK0747354T3 (fr)
ES (1) ES2148685T3 (fr)
GR (1) GR3034523T3 (fr)
HU (1) HU222046B1 (fr)
IL (1) IL118349A (fr)
NO (1) NO304829B1 (fr)
NZ (1) NZ286748A (fr)
PL (1) PL184660B1 (fr)
PT (1) PT747354E (fr)
RU (1) RU2165925C2 (fr)
SG (1) SG70572A1 (fr)
TW (1) TW384284B (fr)
ZA (1) ZA964327B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
HUP0002449A3 (en) * 1997-05-30 2001-12-28 Bristol Myers Squibb Company W Process for producing 3-fluoro oxindole derivatives and intermediates of the preparation
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
WO1999009983A1 (fr) * 1997-08-28 1999-03-04 Bristol-Myers Squibb Company Derives de 4-aryl-3-aminoquinoleine-2-one comme modulateurs de canal potassium
AU5487199A (en) * 1998-08-14 2000-03-06 Elan Pharmaceuticals, Inc. Novel esk potassium channel polypeptide and polynucleotide compositions
WO2000033834A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Utilisation de derives d'isatine en tant qu'agents d'activation de canaux ioniques
BR9915744A (pt) * 1998-12-04 2001-08-21 Bristol Myers Squibb Co Derivados 4-arilquinolin-2-ona 3-substituìdos como moduladores do canal de potássio
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
ATE373642T1 (de) * 1999-08-03 2007-10-15 Abbott Lab Kalium kanalaktivatoren
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US20030181507A1 (en) * 2000-06-29 2003-09-25 Jensen Bo Skaaning Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
JP2004502665A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
CA2438805A1 (fr) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Derives de fluoro oxindole en tant que modulateurs de canaux potassium kcnq
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
WO2003002122A1 (fr) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Derives de beta-hydroxyamine utiles dans le traitement de la maladie d'alzheimer
WO2003080047A1 (fr) * 2002-03-20 2003-10-02 Bristol-Myers Squibb Company Promedicaments phosphates de fluorooxindoles
WO2004002962A1 (fr) * 2002-06-26 2004-01-08 Poseidon Pharmaceuticals A/S Nouveaux derives de benzimidazol-2-one et utilisation
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP2006513154A (ja) * 2002-10-21 2006-04-20 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド カリウムチャネルおよび／または皮質ニューロン活性モジュレーターとしての、ｎ−フェニルアントラニル酸および２−ベンズイミダゾロンの誘導体
KR100456679B1 (ko) * 2002-11-14 2004-11-10 현대모비스 주식회사 차량의 조수석 에어백의 장착구조
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7524664B2 (en) 2003-06-17 2009-04-28 California Institute Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
MXPA06000538A (es) * 2003-07-15 2006-03-30 Smithkline Beecham Corp Compuestos novedosos.
WO2005035498A1 (fr) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
HU0500157D0 (en) * 2005-02-01 2005-04-28 Sanofi Aventis New compounds
HUP0500167A2 (en) * 2005-02-02 2007-03-28 Sanofi Aventis Optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and process for producing them
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013064A (es) * 2005-04-24 2008-01-16 Wyeth Corp Metodo para modular la funcion de la vejiga.
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
CA2615007A1 (fr) * 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Derives de benzimidazole tels que 5-ht6, 5-ht24
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
PA8720901A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Tratamiento del dolor
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
KR20080105105A (ko) * 2006-03-24 2008-12-03 와이어쓰 인지 장애 및 기타 장애의 치료방법
US8252559B2 (en) * 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8026085B2 (en) * 2006-08-04 2011-09-27 California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
EP2203411B1 (fr) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. Dérivés de l'acide n-phénylanthranilique et leurs utilisations
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
JP2010540628A (ja) * 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としてのｎ−置換されたオキシインドリン誘導体
KR100985286B1 (ko) * 2007-12-28 2010-10-04 주식회사 포스코 내지연파괴 특성이 우수한 고강도 고망간강 및 제조방법
EP2540295A1 (fr) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions pour le traitement du syndrome du X fragile
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
ES2767707T3 (es) * 2015-04-29 2020-06-18 Janssen Pharmaceutica Nv Compuestos de indolona y su uso como moduladores de receptor AMPA
AU2018225758A1 (en) 2017-02-24 2019-09-05 Ovid Therapeutics Inc. Methods of treating seizure disorders
AU2018349376A1 (en) 2017-10-09 2020-05-07 Ramot At Tel-Aviv University Ltd. Modulators of potassium ion and TRPV1 channels and uses thereof
US11819909B2 (en) * 2019-01-25 2023-11-21 Jfe Steel Corporation Method for manufacturing high-manganese steel cast slab and method for manufacturing high-manganese steel slab or steel sheet
CN110240558B (zh) * 2019-07-10 2022-05-27 上海华理生物医药股份有限公司 一种Flindokalner消旋体的新合成方法
KR102209406B1 (ko) * 2019-11-21 2021-01-29 주식회사 포스코 미세한 주조조직을 갖는 고망간강 및 그 제조방법과 이를 이용한 고망간 강판
EP3912625A1 (fr) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Nouveaux ouvreurs de canaux potassiques maxi-k pour le traitement de troubles liés à l'x fragile
WO2025233532A1 (fr) 2024-05-10 2025-11-13 Les Laboratoires Servier Dispositifs d'ouverture de canaux potassiques maxi-k et leurs applications thérapeutiques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114351A1 (de) * 1981-04-09 1982-11-04 Hoechst Ag, 6000 Frankfurt "oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung"
DE3529994A1 (de) * 1985-08-22 1987-02-26 Hoechst Ag Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
CZ279488B6 (cs) * 1990-09-25 1995-05-17 Lonza A.G. Způsob mikrobiologické výroby hydroxylovaných heterocyklů
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
PL314672A1 (en) 1996-12-09
RU2165925C2 (ru) 2001-04-27
ZA964327B (en) 1997-11-28
HUP9601547A1 (en) 1997-09-29
KR970001324A (ko) 1997-01-24
HU9601547D0 (en) 1996-08-28
US5602169A (en) 1997-02-11
US5565483A (en) 1996-10-15
SG70572A1 (en) 2000-02-22
DE69609772D1 (de) 2000-09-21
CN1144800A (zh) 1997-03-12
IL118349A (en) 2000-07-26
NO962232L (no) 1996-12-09
KR100432157B1 (ko) 2004-10-06
JPH08333336A (ja) 1996-12-17
CA2176183A1 (fr) 1996-12-08
AU707760B2 (en) 1999-07-22
EP0747354B1 (fr) 2000-08-16
EP0747354A1 (fr) 1996-12-11
HK1003301A1 (en) 1998-10-23
BR1100180A (pt) 2000-03-14
CA2176183C (fr) 2010-03-30
HU222046B1 (hu) 2003-04-28
NO962232D0 (no) 1996-05-31
AR004493A1 (es) 1998-12-16
CZ161896A3 (en) 1997-03-12
CN1076348C (zh) 2001-12-19
JP4011135B2 (ja) 2007-11-21
DE69609772T2 (de) 2001-04-12
DK0747354T3 (da) 2000-09-18
GR3034523T3 (en) 2000-12-29
ES2148685T3 (es) 2000-10-16
CZ289248B6 (cs) 2001-12-12
PL184660B1 (pl) 2002-11-29
PT747354E (pt) 2000-11-30
NZ286748A (en) 1998-08-26
ATE195515T1 (de) 2000-09-15
AU5475796A (en) 1996-12-19
IL118349A0 (en) 1996-09-12
TW384284B (en) 2000-03-11

Similar Documents

Publication Publication Date Title
DK0747354T3 (da) 3-substituerede oxindolderivater som kaliumkanalmodulatorer
DK1133474T3 (da) 3-Substituerede 4-arylquinolin-2-onderivater som kaliumkanal-modulatorer
AU2647597A (en) Oxindole derivatives
NO974043D0 (no) Indolderivater som EAA-antagonister
FI962969A0 (fi) Indolijohdannaisia 5-HT1:n agonisteina
EP1011677A4 (fr) Derives de 4-aryl-3-aminoquinoleine-2-one comme modulateurs de canal potassium
NO975880L (no) Formylderivater anvendt som ikke-ioniske kontrastmidler
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
KR970702865A (ko) 신규 카르바페넴 유도체(Novel Carbapenem Derivatives)
DE69736371D1 (de) Bieten um Bandbreite
AU6370196A (en) Indole derivatives
DK0725061T3 (da) Substituerede indolderivater
FI971492L (fi) Indolijohdannaiset 5-HT1-tyyppisinä agonisteina
NO975811D0 (no) Ny anvendelse for pyrrolderivater
ATE210117T1 (de) Indolderivate als melatoninanaloge
AU6370296A (en) Indole derivatives
AU6370096A (en) Indole derivatives
DE59605373D1 (de) Substituierte Indol-Derivate
FI960434A0 (fi) Slaganordning som arbetar med hydrauliskt tryck

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees